Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses How Did The Patients Do: Out Of 13 Patients Treated In The Adjuvant Setting 2 Progressed & 11 Remains Disease Free.
How Did The Patients Do: Out Of 13 Patients Treated In The Adjuvant Setting 2 Progressed & 11 Remains Disease Free
